Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistance
Rachel W Anantha,
Srilatha Simhadri,
Tzeh Keong Foo,
Susanna Miao,
Jingmei Liu,
Zhiyuan Shen,
Shridar Ganesan,
Bing Xia
Affiliations
Rachel W Anantha
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Radiation Oncology, Rutgers, The State University of New Jersey, New Brunswick, United States
Srilatha Simhadri
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Radiation Oncology, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, United States
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Radiation Oncology, Rutgers, The State University of New Jersey, New Brunswick, United States
Susanna Miao
Department of Genetics, School of Arts and Sciences, Rutgers, The State University of New Jersey, Piscataway, United States
Jingmei Liu
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Radiation Oncology, Rutgers, The State University of New Jersey, New Brunswick, United States
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Radiation Oncology, Rutgers, The State University of New Jersey, New Brunswick, United States
Shridar Ganesan
Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Radiation Oncology, Rutgers, The State University of New Jersey, New Brunswick, United States; Department of Medicine, Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, United States
BRCA1 plays a critical role in homology-directed repair (HDR) of DNA double strand breaks, and the repair defect of BRCA1-mutant cancer cells is being targeted with platinum drugs and poly (ADP-ribose) polymerase (PARP) inhibitors. We have employed relatively simple and sensitive assays to determine the function of BRCA1 variants or mutants in two HDR mechanisms, homologous recombination (HR) and single strand annealing (SSA), and in conferring resistance to cisplatin and olaparib in human cancer cells. Our results define the functionality of the top 22 patient-derived BRCA1 missense variants and the contribution of different domains of BRCA1 and its E3 ubiquitin ligase activity to HDR and drug resistance. Importantly, our results also demonstrate that the BRCA1-PALB2 interaction dictates the choice between HR and SSA. These studies establish functional and mutational landscapes of BRCA1 for HDR and therapy resistance, while revealing novel insights into BRCA1 regulatory mechanisms and HDR pathway choice.
